兰尼单抗
 | 此條目没有列出任何参考或来源。 (2014年3月10日) |
 | 此條目可参照英語維基百科相應條目来扩充。 (2023年12月3日) |
| 单克隆抗体 | |
|---|---|
| 种类 | Fab片段 |
| 目標 | 血管内皮生长因子A（VEGF-A） |
| 臨床資料 | |
| 商品名 | Lucentis, others |
| 生物相似藥 | Ranibizumab-nuna,[1] Ranibizumab-eqrn,[2] Byooviz,[1][3] Cimerli,[2] Ranivisio,[4] Susvimo,[5] Ximluci[6] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607044 |
| 核准狀況 |
|
| 懷孕分級 | |
| 给药途径 | 静脉注射 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 藥物動力學數據 | |
| 生物半衰期 | 约9天[10] |
| 识别信息 | |
| CAS号 | 347396-82-1  |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| 化学信息 | |
| 化学式 | C2158H3282N562O681S12 |
| 摩尔质量 | 48,379.97 g·mol−1 |
兰尼单抗（英語：Ranibizumab，也译为雷珠单抗，商品名Lucentis）是一种单克隆抗体片段（FAB），其与贝伐单抗（bevacizumab）是从相同亲本鼠抗体获得。它比母体分子小得多，能更紧密的结合到血管内皮生长因子-A(VEGF-A)。它是一种血管生成抑制剂(angiogenesis inhibitor)，已被批准用于治疗的“湿”型老年黄斑变性。
参考资料
[编辑]- ^ 1.0 1.1 1.2 Byooviz Nuna- ranibizumab injection, solution. DailyMed. 2022-04-27 [2022-08-02]. （原始内容存档于2022-08-03）.
- ^ 2.0 2.1 2.2 Cimerli- ranibizumab-eqrn injection, solution. DailyMed. 2022-10-19 [2023-01-21]. （原始内容存档于2023-01-21）.
- ^ 3.0 3.1 Byooviz EPAR. European Medicines Agency. 2021-06-23 [2021-09-09]. （原始内容存档于2021-09-10）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 4.0 4.1 Ranivisio EPAR. European Medicines Agency (EMA). 2022-06-20 [2022-10-06]. （原始内容存档于2022-10-06）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 5.0 5.1 Susvimo- ranibizumab injection, solution. DailyMed. [2021-12-19]. （原始内容存档于2021-12-19）.
- ^ 6.0 6.1 Ximluci EPAR. European Medicines Agency. 2022-09-14 [2023-03-03]. （原始内容存档于2023-03-13）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 7.0 7.1 AusPAR: Ranibizumab. Therapeutic Goods Administration (TGA). 2014-12-09 [2021-09-20]. （原始内容存档于2021-09-21）.
- ^ 8.0 8.1 https://www.tga.gov.au/resources/auspmd/byooviz [裸露网址]
- ^ Summary Basis of Decision - Byooviz. Health Canada. 2022-08-12 [2022-09-29]. （原始内容存档于2022-09-29）.
- ^ 10.0 10.1 Lucentis- ranibizumab injection, solution. DailyMed. [2021-09-20]. （原始内容存档于2021-09-21）.
- ^ Lucentis EPAR. European Medicines Agency. 2018-09-17 [2021-09-09]. （原始内容存档于2021-09-10）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
外部链接
[编辑]- 官方网站 Genentech